MiNK Therapeutics agenT-797 Data

MiNK Therapeutics announced new clinical and translational data for its investigational off-the-shelf iNKT cell therapy, Agent 797, presented at the American Thoracic Society International Conference 2026 and published in Clinical Immunology Communications. The data describes the use of sequential immunotherapy with Agent 797 and N-803 (Anktiva), an FDA-approved IL-15 superagonist developed by ImmunityBio, in a critically ill patient with unresolving disseminated Coccidioides immitis infection, severe acute respiratory distress syndrome (ARDS), and concurrent hospital-acquired Pseudomonas aeruginosa pneumonia. The treatment showed suppression of fungal and bacterial pathogens, immune cell recruitment, reduced inflammatory signaling, and activation of tissue repair. These findings support MiNK Therapeutics' ongoing randomized Phase 2 clinical trial evaluating Agent 797 in adults with severe acute lung injury and critical illness.